DrugDev, Exostar Collaborate on Linked Identifiers
The collaboration will allow joint customers to securely combine data from all site-facing applications using single sign-on with non-site facing data sources.
DrugDev and Exostar will combine their unique global identifiers for clinical operations personnel and facilities to address identity credential duplication and missing or incorrect records in systems.
Exostar offers SAM, a turnkey, cloud-based identity and access management solution that delivers single sign-on application access with multi-factor authentication. DrugDev provides its universal identifier called the DrugDev Golden Number for tracking persons and facilities across multiple data sources. The linkage will allow joint customers to securely combine data from all site-facing applications using single sign-on with non-site facing data sources.
Read the full release.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
